10.43
0.14 (1.36%)
| Previous Close | 10.29 |
| Open | 10.30 |
| Volume | 1,265,683 |
| Avg. Volume (3M) | 1,604,378 |
| Market Cap | 3,275,847,168 |
| Price / Earnings (TTM) | 1,043.00 |
| Price / Sales | 1.15 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -0.46% |
| Operating Margin (TTM) | 14.51% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Quarterly Earnings Growth (YOY) | -49.70% |
| Current Ratio (MRQ) | 1.40 |
| Operating Cash Flow (TTM) | 306.92 M |
| Levered Free Cash Flow (TTM) | 311.48 M |
| Return on Assets (TTM) | 6.67% |
| Return on Equity (TTM) | -881.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Amneal Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.25 |
|
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 46.75% |
| % Held by Institutions | 43.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tpg Gp A, Llc | 30 Jun 2025 | 12,328,767 |
| Nantahala Capital Management, Llc | 30 Jun 2025 | 4,367,438 |
| Blackbarn Capital Partners Lp | 30 Jun 2025 | 3,446,570 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Oct 2025 | Announcement | Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) |
| 30 Sep 2025 | Announcement | Amneal to Report Third Quarter 2025 Results on October 30, 2025 |
| 26 Sep 2025 | Announcement | Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) |
| 23 Sep 2025 | Announcement | Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% |
| 11 Sep 2025 | Announcement | Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution |
| 04 Sep 2025 | Announcement | Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension |
| 05 Aug 2025 | Announcement | Amneal Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |